Clinical experience of using double bronchodilation therapy in patients with COPD
https://doi.org/10.21518/2079-701X-2019-15-7-10
Abstract
Chronic obstructive pulmonary disease is today one of the socially significant diseases, and its treatment remains a major medical problem.
Currently, the main goals of treating patients with COPD are: eliminating symptoms and improving the quality of life, preventing exacerbations and reducing future risks, slowing the progression of the disease and reducing mortality.
The article presents a clinical case from the practice of a patient with COPD who received tiotropium bromidi as monotherapy. The patient had significant impaired airway patency during spirometry, a decrease in exercise tolerance. The patient was assigned a new representative of combination preparations with a 24-hour action – Anoro Ellipta® (Vilanterol + Umeklidiniy) 22/55 mcg, with a new drug delivery vehicle. After 6 months of therapy with Anoro Ellipt®, the patient has increased exercise tolerance, improved pulmonary function, as well as quality of life.
About the Authors
I. V. Demko
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University;
Regional clinical hospital
Russian Federation
Russian Federation
Dr. of Sci. (Med), Professor, Head of the Department of Internal Diseases and Immunology with a course of PE, 1, Partizana Zheleznyaka St., Krasnoyarsk, 660022;
head of pulmonary center, 3, Partizana Zheleznyaka St., Krasnoyarsk, 660022
M. G. Mamayeva
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University;
Regional clinical hospital
Russian Federation
Russian Federation
Cand. of Sci. (Med), Assistant of the Department of Internal Diseases and Immunology with a course of PE, Pulmonologist of the Department of Pulmonology, 1, Partizana Zheleznyaka St., Krasnoyarsk, 660022;
Regional clinical hospital, 3, Partizana Zheleznyaka St., Krasnoyarsk, 660022
N. V. Gordeyeva
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University;
Regional clinical hospital
Russian Federation
Russian Federation
Cand. of Sci. (Med), associate professor of the Department of Internal Diseases and Immunology with a course of PE, 1, Partizana Zheleznyaka St., Krasnoyarsk, 660022;
Pulmonologist, Regional State Budgetary Healthcare Institution «Regional clinical hospital»; 3, Partizana Zheleznyaka St., Krasnoyarsk, 660022
I. A. Solov’yeva
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University;
Regional clinical hospital
Russian Federation
Russian Federation
Dr. of Sci. (Med), associate professor of the Department of Internal Diseases and Immunology with a course of PE, 1, Partizana Zheleznyaka St., Krasnoyarsk, 660022;
Pulmonologist, 3, Partizana Zheleznyaka St., Krasnoyarsk, 660022
A. Yu. Kraposhina
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University;
Regional clinical hospital
Russian Federation
Russian Federation
Cand. of Sci. (Med), associate professor of the Department of Internal Diseases and Immunology with a course of PE, 1, Partizana Zheleznyaka St., Krasnoyarsk, 660022;
Pulmonologist, 3, Partizana Zheleznyaka St., Krasnoyarsk, 660022
References
1. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report updated 2018. 80 p. Available at: https://goldcopd.org/wp-content/ uploads/2018/11/GOLD-2019-v1.7-FINAL14Nov2018-WMS.pdf.
2. World Health Organization. Evidenceinformed policy-making. 2016. Available at: http://www.who.int/evidence.
3. Sviderskaya L.N., Simakova V.M., Demko I.V., Hendogina V.T., Kudryavceva A.N., Tret’yak T.V. et al. Comparative assessment of the organization of access control and quality of medical care in the conditions of the regional consultative clinic. Sibirskoe medicinskoe obozrenie = Siberian Medical Review. 2016;(5):53-64. (In Russ.) Available at: https://elibrary.ru/item.asp?id=27487911.
4. Cazzola M., Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. doi: 10.1016/j.pupt.2010.03.003.
5. Vizel’ A.A., Vizel’ I.YU, Bakunina E.A. Chronic obstructive pulmonary disease modern approaches to therapy. Meditsinskiy sovet = Medical Council. 2016;(15):6-10. doi: 10.21518/2079-701X-2016-15-6-10.
6. Spyratos D., Sichletidis L. Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review. Ther Clin Risk Manag. 2015;11:481-487. doi: 10.2147/TCRM.S67491.
7. Rodrigo G.J., Neffen H. A systematic review on the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD. Chest. 2015;148(2):397-407. doi: 10.1378/chest.15-0084.
8. Saeed H., Salem H.F., Rabea H. et al. Effect of Human Error, Inhalation Flow, and Inhalation Volume on Dose Delivery from Ellipta® DryPowder Inhaler. J Pharm Innov. 2019;14(3):239- 244. doi: 10.1007/s12247-018-9352-y.
9. Prime D., de Backer W., Hamilton M. et al. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on InhalerSpecific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2015;28(6):486-497. doi: 10.1089/jamp.2015.1224.
Review
For citations:
Demko IV, Mamayeva MG, Gordeyeva NV, Solov’yeva IA, Kraposhina AY. Clinical experience of using double bronchodilation therapy in patients with COPD. Meditsinskiy sovet = Medical Council. 2019;(15):7-10. (In Russ.) https://doi.org/10.21518/2079-701X-2019-15-7-10
Views:
536
Email this article 